The 100 billion industry chain grows up!

The biomedicine and health industry is one of Xiamen’s key developmental chain of 100 billion yuan.
In recent years, Xiamen’s biomedicine and health industry has developed rapidly, and an industrial cluster featuring medical devices and diagnostic reagents has been formed
.
According to the recently released third-quarter report, in the first three quarters of 2021, listed companies in the biomedical field in Xiamen have collectively risen
.
Among them, Xiamen Technological Innovation Co.
, Ltd.
, Tebao Biotechnology, achieved a year-on-year increase of approximately 45% in total operating income to 810 million yuan in the first three quarters of this year; net profit attributable to parent companies increased by approximately 67% year-on-year to 130 million yuan
.
In the first three quarters of this year, Aide Bio's total operating income increased by about 33% year-on-year, reaching 650 million yuan; net profit attributable to the parent increased by 40% year-on-year to 180 million yuan
.
In the first three quarters of Dabo Medical's total operating income increased by about 18% year-on-year to 1.
3 billion yuan; net profit attributable to the parent increased by 6% year-on-year to 450 million yuan
.
Luyan Pharmaceuticals achieved a year-on-year increase of approximately 14% in total operating income to RMB 13.
002 billion; net profit attributable to its parent increased by approximately 8% year-on-year to RMB 229 million
.
The biomedicine and health industry is one of Xiamen’s key industries.
The special plan for the development of strategic emerging industries in Xiamen’s "14th Five-Year Plan" pointed out that the "5+X" key areas will be fully developed, that is, to create a new generation of information technology.
Pillar industry, strengthen the two emerging leading industries of biomedicine and health, new materials and new energy, develop two characteristic landmark industries of digital creativity and marine high-tech, and advance the layout of flexible electronics, third-generation semiconductors, aerospace, intelligent manufacturing equipment, X future tracks such as precision medicine and green and low-carbon technology
.
Among them, the plan is clearly in the field of biomedicine and health, focusing on the development of new drugs, high-performance medical devices, smart medical and health services, functional foods, digital health equipment and other fields
.
It is understood that Xiamen has formed an industrial cluster featuring medical devices and diagnostic reagents, and has strong original innovation capabilities in the fields of new vaccines, genetic engineering protein drugs, and chemical drug preparation improvements
.
Today there are more than 1,000 companies in the biomedical and health field in Xiamen, including 358 national high-tech companies, 204 small technology giants, and 10 listed companies
.
In the first half of this year, Xiamen's biomedicine and health industry is expected to achieve a year-on-year increase of approximately 21% in output value, reaching 47.
3 billion yuan
.
Among them, 59 companies have output value or revenue exceeding 100 million yuan, some companies are showing a trend of rapid growth, 67 companies with revenue growth exceeding 100%
.
Technology and talents are the core competitiveness of the biopharmaceutical industry.
It is understood that for a long time, Xiamen has been doing a good job in talent work from multiple dimensions such as “introducing, nurturing, using, managing, and retaining”, and formulating special policies for industrial talents.
Provide comprehensive support for tax incentives, talent housing, spouse employment, children’s education, etc.
, to achieve multi-dimensional protection from entrepreneurship to life, and innovate the evaluation model of "enterprise independent evaluation + industry professional evaluation + market development evaluation", and implement professional titles in the biomedical industry Review reforms and establish a more accurate and scientific talent evaluation mechanism
.
In the next step, Xiamen City will revise the "Measures for Accelerating the High-Quality Development of the Biomedicine Industry", relying on Xiamen University to prepare for the establishment of the "International Bioeconomy Research Institute" to carry out biotechnology application research; to create a "National Traditional Chinese Medicine Industry-University-Research Collaborative Innovation Experimental Zone" ”, the layout of the Chinese Medicine Industry-University-Research Collaborative Innovation Research Institute and the Chinese Medicine Clinical Diagnosis and Treatment Center
.
window.
_bd_share_config={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"32"},"share":{},"image":{"viewList":["weixin","sqq","qzone","tsina","tqq"," tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:", "viewSize":"24"},"selectShare":{"bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu", "tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}};with(document)0[(getElementsByTagName('head ')[0]||body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js ?cdnversion='+~(-new Date()/36e5)]; Keywords: 100 billion industrial chain grows! Xiamen Biopharmaceutical listed companies collectively rose in the first three quarters Previous post: Hainan issued 14 "Drug Production Licenses" (B Certificates), injecting new vitality into the development of medicine [Information Search] [Add to Favorites] [Tell a Friend] [Print This Article] [Close Window] A total of 0 similar information [View all] Related comments com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; Keywords: 100 billion industry chain grows! Xiamen Biopharmaceutical listed companies collectively rose in the first three quarters Previous post: Hainan issued 14 "Drug Production Licenses" (B Certificates), injecting new vitality into the development of medicine [Information Search] [Add to Favorites] [Tell a Friend] [Print This Article] [Close Window] A total of 0 similar information [View all] Related comments com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; Keywords: 100 billion industry chain grows! Xiamen Biopharmaceutical listed companies collectively rose in the first three quarters Previous post: Hainan issued 14 "Drug Production Licenses" (B Certificates), injecting new vitality into the development of medicine [Information Search] [Add to Favorites] [Tell a Friend] [Print This Article] [Close Window] A total of 0 similar information [View all] Related comments